Antares Pharma, Inc. (ATRS) Financial Statements (2024 and earlier)

Company Profile

Business Address 100 PRINCETON SOUTH
EWING, NJ 08628
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2022
MRQ
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 65,91353,13745,72127,89231,55527,715
Cash and cash equivalents 65,91353,13723,20127,89226,56227,715
Short-term investments 1,245 22,520 4,993 
Other undisclosed cash, cash equivalents, and short-term investments (1,245)     
Receivables 83,00842,22135,07418,97611,8789,073
Inventory, net of allowances, customer advances and progress billings 11,54418,21616,00011,3509,2755,327
Inventory 11,54418,21616,00011,3509,2755,327
Contract with customer, asset, after allowance for credit loss 8,0308,1408,23510,442
Deferred costs     5051,773
Other undisclosed current assets 5,7774,8773,4162,6482,3231,376
Total current assets: 174,272126,591108,44671,30855,53645,264
Noncurrent Assets
Operating lease, right-of-use asset 3,7744,6215,463
Property, plant and equipment 26,01524,02015,96114,89516,15817,867
Intangible assets, net (including goodwill) 18,9748,7881,5731,9262,4963,140
Goodwill 1,0951,0951,0951,0951,0951,095
Intangible assets, net (excluding goodwill) 17,8797,6934788311,4012,045
Deferred income tax assets 33,04346,982 
Other noncurrent assets 1,4271,5291,30814814854
Total noncurrent assets: 83,23385,94024,30516,96918,80221,061
TOTAL ASSETS: 257,505212,531132,75188,27774,33866,325
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 52,09941,82929,42823,13212,93913,758
Accounts payable 17,05616,19412,90511,1355,9577,885
Accrued liabilities 35,04325,63516,52311,9976,9825,873
Deferred revenue 4,4273,9431,738
Debt 1,50016,2301,2493,043  
Deferred revenue and credits2,7946,149
Contract with customer, liability1,018
Other undisclosed current liabilities 9041,203    
Total current liabilities: 58,93063,20532,41527,19315,73319,907
Noncurrent Liabilities
Long-term debt and lease obligation 22,81729,48545,83622,08324,858 
Long-term debt, excluding current maturities 18,24124,66940,39522,08324,858 
Liabilities, other than long-term debt  726  2001,200
Deferred revenue and credits2001,200
Other liabilities  726    
Operating lease, liability 4,5764,8165,441
Other undisclosed noncurrent liabilities (4,576)     
Total noncurrent liabilities: 22,81730,21145,83622,08325,0581,200
Total liabilities: 81,74793,41678,25149,27640,79121,107
Equity
Equity, attributable to parent, including: 175,758119,11554,50039,00133,54745,219
Additional paid in capital 351,079340,756332,377314,907302,965297,826
Accumulated other comprehensive loss (685)(683)(702)(703)(700)(714)
Accumulated deficit (176,337)(222,626)(278,827)(276,800)(270,285)(253,445)
Other undisclosed equity, attributable to parent 1,7011,6681,6521,5971,5671,552
Total equity: 175,758119,11554,50039,00133,54745,219
TOTAL LIABILITIES AND EQUITY: 257,505212,531132,75188,27774,33866,325

Income Statement (P&L) ($ in thousands)

3/31/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues 183,982149,599123,86463,55454,51552,222
Revenue, net54,51552,222
Cost of revenue (106,872)(63,078)(50,475)(31,065)(27,466)(28,817)
Cost of goods and services sold (359)(356)(50,475)(31,065)(27,466)(28,817)
Gross profit: 77,11086,52173,38932,48927,04923,405
Operating expenses (49,768)(72,902)(72,397)(36,590)(43,500)(47,522)
Other undisclosed operating income 38,591     
Operating income (loss): 65,93313,619992(4,101)(16,451)(24,116)
Nonoperating expense (3,662)(3,698)(3,019)(2,414)(292)(122)
Other nonoperating income (expense) (51)89530261271(199)
Interest and debt expense (3,611)(3,787)(3,549)(2,675)(1,423) 
Income (loss) from continuing operations before equity method investments, income taxes: 58,6606,134(5,576)(9,190)(18,166)(24,239)
Other undisclosed income from continuing operations before income taxes 3,6113,7873,5492,6751,423 
Income (loss) from continuing operations before income taxes: 62,2719,921(2,027)(6,515)(16,743)(24,239)
Income tax expense (benefit) (15,982)46,280   (100)
Income (loss) from continuing operations: 46,28956,201(2,027)(6,515)(16,743)(24,339)
Income (loss) before gain (loss) on sale of properties:46,28956,201(2,027)(6,515)(16,743)(24,339)
Net income (loss) available to common stockholders, diluted: 46,28956,201(2,027)(6,515)(16,743)(24,339)

Comprehensive Income ($ in thousands)

3/31/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss): 46,28956,201(2,027)(6,515)(16,743)(24,339)
Other comprehensive income (loss) (2)191(3)15(22)
Comprehensive income (loss), net of tax, attributable to parent: 46,28756,220(2,026)(6,518)(16,728)(24,361)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: